Remicade Biosimilar Market

By Disease Indication;

Crohn’s Disease, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Ulcerative Colitis, and Plaque Psoriasis

By Type;

Branded and Biosimilar

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn098461069 Published Date: August, 2025 Updated Date: September, 2025

Remicade Biosimilar Market Overview

Remicade Biosimilar Market (USD Million)

Remicade Biosimilar Market was valued at USD 4,130.19 million in the year 2024. The size of this market is expected to increase to USD 36,688.10 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 36.6%.


Remicade Biosimilar Market

*Market size in USD million

CAGR 36.6 %


Study Period2025 - 2031
Base Year2024
CAGR (%)36.6 %
Market Size (2024)USD 4,130.19 Million
Market Size (2031)USD 36,688.10 Million
Market ConcentrationLow
Report Pages367
4,130.19
2024
36,688.10
2031

Major Players

  • Pfizer Inc
  • Celltrion Healthcare
  • Samsung Bioepis
  • Amgen Inc
  • Mylan N.V
  • Sandoz (a Novartis division)
  • Biocon
  • Hospira (a Pfizer subsidiary)
  • Merck & Co Inc
  • Teva Pharmaceutical Industries Ltd

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Remicade Biosimilar Market

Fragmented - Highly competitive market without dominant players


The Remicade Biosimilar Market is experiencing rapid growth as healthcare systems prioritize affordable biologics. Nearly 60% of patients with autoimmune conditions now opt for biosimilars, supported by proven therapeutic effectiveness. This demonstrates the crucial role biosimilars play in expanding access to essential treatments.

Rising Adoption in Autoimmune Disease Management
Growing cases of rheumatoid arthritis, Crohn’s disease, and similar conditions have accelerated biosimilar adoption. Close to 52% of biologic treatments for inflammatory diseases are now prescribed as biosimilars, reflecting higher clinical confidence and patient acceptance. Their rising usage emphasizes a strong preference for reliable alternatives to costly biologics.

Cost Efficiency Driving Market Expansion
The affordability of biosimilars is a key driver in their adoption. Data shows that biosimilars can reduce overall therapy costs by nearly 45%, helping patients access necessary treatments more easily. This economic benefit motivates healthcare providers to increase reliance on Remicade biosimilars in routine care.

Technological Advancements Enhancing Reliability
Advances in biomanufacturing technology have strengthened the performance of biosimilars. Around 40% of the latest biosimilars incorporate innovations that improve molecular stability and clinical outcomes. These enhancements ensure biosimilars consistently deliver results comparable to original biologics, strengthening their role in advanced therapies.

Growing Use Across Therapeutic Applications
The scope of Remicade biosimilars continues to broaden across various autoimmune and inflammatory conditions. More than 55% of therapeutic protocols in ulcerative colitis, psoriasis, and ankylosing spondylitis now include biosimilars. This widespread use highlights their value in long-term treatment solutions and positions them as an essential component of modern healthcare.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Disease Indication
    2. Market Snapshot, By Type
    3. Market Snapshot, By Region
  4. Remicade Biosimilar Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising Prevalence of Chronic Diseases
        2. Increasing Demand for Cost-Effective Treatments
        3. Favorable Regulatory Environments
      2. Restraints
        1. High Development Costs
        2. Regulatory and Approval Challenges
        3. Physician and Patient Reluctance
      3. Opportunities
        1. Expansion in Emerging Markets
        2. Advances in Biotechnology
        3. Strategic Collaborations and Partnerships
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Remicade Biosimilar Market, By Disease Indication, 2021 - 2031 (USD Million)
      1. Crohn’s Disease
      2. Rheumatoid Arthritis
      3. Ankylosing Spondylitis
      4. Psoriatic Arthritis
      5. Ulcerative Colitis
      6. Plaque Psoriasis
    2. Remicade Biosimilar Market, By Type, 2021 - 2031 (USD Million)

      1. Branded

      2. Biosimilar

    3. Remicade Biosimilar Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Pfizer Inc
      2. Celltrion Healthcare
      3. Samsung Bioepis
      4. Amgen Inc
      5. Mylan N.V
      6. Sandoz (a Novartis division)
      7. Biocon
      8. Hospira (a Pfizer subsidiary)
      9. Merck & Co Inc
      10. Teva Pharmaceutical Industries Ltd
  7. Analyst Views
  8. Future Outlook of the Market